Impact of Folates in the Care of the Male Infertility (FOLFIV)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Unexplained male infertility is increasing, and, nowadays, the investigators only can propose palliative treatment, as In VITRO Fertilization (IVF). The folate metabolism is a key for the maintenance of genome integrity. A dysfunction in this pathway can be responsible of spermatogenesis defects, and further, of infertility. Few assays have shown that folate treatment can improve sperm parameters and fertility, till 30% in some of theses studies. The purpose of the investigators study is to demonstrate the impact of folates treatment on improvement of sperm parameters and on the rate of success of in VITRO fertilization procedures.
| Condition | Intervention | Phase |
|---|---|---|
|
Male Infertility |
Drug: Folic acid Drug: placebo of folic acid |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Impact of Folates in the Care of the Male Infertility |
- The rates of pregnancy in IVF according to the arm of treatment [ Time Frame: 3 months ] [ Designated as safety issue: No ]Estimate the efficiency of the treatment by folic acid at infertile men on the improvement of improvement of the pregnancy rates in IVF
- The rate of improvement of the sperm parameters with acid folic treatment [ Time Frame: 3 months ] [ Designated as safety issue: No ]Estimate the efficiency of the treatment by folic acid on the sperm parameters
- The rate of improvement of the nuclear quality of gametes with acid folic treatment [ Time Frame: 3 months ] [ Designated as safety issue: No ]Estimate the efficiency of the treatment by folic acid on the nuclear quality of gametes
- The rate of pregnancy of couple with infertile men treated by folic acid according to the methylene-tetrahydrofolate reductase (MTHFR) genotype [ Time Frame: 3 months ] [ Designated as safety issue: No ]Estimate the impact of the methylene-tetrahydrofolate reductase (MTHFR) genotype of the patients on the rates of pregnancy according to the arm of treatment
- The difference between the methylene-tetrahydrofolate reductase (MTHFR) genotype of the patients on sperm parameters according to the arm of treatment [ Time Frame: 3 months ] [ Designated as safety issue: No ]Estimate the impact of methylene-tetrahydrofolate reductase (MTHFR) genotype of the patients on sperm parameters according to the arm of treatment
| Estimated Enrollment: | 780 |
| Study Start Date: | November 2011 |
| Estimated Study Completion Date: | March 2015 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Folic acid
tablets of 5 mg of folic acid
|
Drug: Folic acid
Taking of folic acid 15 mg per day by hanging oral route during 3 at 4 months
Other Name: Folic acid
|
|
Placebo Comparator: Placebo
Tablets of placebo of folic acid
|
Drug: placebo of folic acid
Taking of placebo of folic acid by hanging oral route during 3 at 4 months
Other Name: placebo of folic acid
|
Detailed Description:
The folate impact in the treatment of male infertility will be reviewed by this large multicentric randomized controlled double-blind study comparing 2 parallel groups of 390 patients. In each group: folic acid 15mg/day versus placebo, orally for at least 3 months (duration of a cycle of spermatogenesis). This assay will evaluate the effectiveness of treatment with folic acid compared to its placebo in infertile men with the outcome of IVF+/-ICSI techniques (pregnancy rate). It will also assess the impact of folate therapy on sperm parameters, and further, the impact on abnormal sperm DNA methylation profiles.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Couple whose man is from 18 to 60 years old
- Couple whose man presents an infertility indicating a care in VITRO fertilization with or without intracytoplasmic sperm injection (IVF +/- ICSI)
- Couple whose spouse is from 18 to 38 years old
- Couple whose spouse do not present particular factors of infertility
- Couple Taken care in IVF +/- ICSI
- Couple with social insurance
- 2 members of the couple having signed the consent
Exclusion Criteria:
- Etiology of not genetic known male infertility : infertility of neoplastic origine, infertility of definitive obstructive origin
- Presence of a factor of feminine infertility : A definitive infertility tubal, Turned out ovarian incapacity
- Male infertility requiring the appeal to some sperm testicular or in some frozen sperm- Men or women attend of HIV or hepatitis B or C
- Epileptic men
- Men under anti-folic treatment
- Men presenting a big sensibility to the folic acid or to one of the constituents of the drug
- Couple of which one of the partners refuses to participate in the study
Contacts and Locations| Contact: Emmanuelle Mathieu-D'Argent, MD | + 33 (0) 1 56 01 68 69 | emmanuelle.mathieu@tnn.aphp.fr |
| Contact: Célia Ravel, MD | + 33 (0) 1 56 01 78 01 | celia.ravel@tnn.aphp.fr |
| France | |
| Service of gynaecology-obstetrics and medicine of the reproduction, Tenon Hospital - APHP | Recruiting |
| Paris, France, 75020 | |
| Contact: Emmanuelle Mathieu-D'Argent, MD + 33 (0) 1 56 01 68 69 emmanuelle.mathieu@tnn.aphp.fr | |
| Contact: Célia Ravel, MD | |
| Principal Investigator: Emmanuelle Mathieu - d'Argent, MD | |
| Principal Investigator: | Emmanuelle MATHIEU - D'ARGENT, MD | TENON Hospital - APHP |
More Information
Publications:
| Responsible Party: | Assistance Publique - Hôpitaux de Paris |
| ClinicalTrials.gov Identifier: | NCT01407432 History of Changes |
| Other Study ID Numbers: | P 100108 |
| Study First Received: | June 28, 2011 |
| Last Updated: | July 25, 2012 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) France: The Commission nationale de l’informatique et des libertés |
Keywords provided by Assistance Publique - Hôpitaux de Paris:
|
Male infertility folic acid in VITRO fertilization sperm parameters MTHFR genotype |
Additional relevant MeSH terms:
|
Infertility Infertility, Male Genital Diseases, Male Genital Diseases, Female Folic Acid Vitamin B Complex Hematinics |
Vitamins Micronutrients Growth Substances Physiological Effects of Drugs Pharmacologic Actions Hematologic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on June 18, 2013